HiFiBiO

Paris, France Founded: 2013 • Age: 13 yrs
Antibody-based drugs are discovered using a specialized technology platform.

About HiFiBiO

HiFiBiO is a company based in Paris (France) founded in 2013 by Liang Schweizer.. HiFiBiO has raised $179.5 million across 3 funding rounds from investors including Kite Pharma, Legend Holdings and Mirae Asset Financial Services. HiFiBiO has completed 1 acquisition, including H-Immune. HiFiBiO offers products and services including DIS® Platform, EMUNKITUG, and HFB200604. HiFiBiO operates in a competitive market with competitors including GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others.

  • Headquarter Paris, France
  • Founders Liang Schweizer
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Hifibio Therapeutics, Inc.
Operational Areas
Healthcare → Biotechnology, Genomics & Life Sciences Research
Healthcare → Biotechnology, Genomics & Life Sciences Research
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $179.5 M (USD)

    in 3 rounds

  • Latest Funding Round
    $75 M (USD), Series D

    Jun 14, 2021

  • Investors
    Kite Pharma

    & 19 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of HiFiBiO

HiFiBiO offers a comprehensive portfolio of products and services, including DIS® Platform, EMUNKITUG, and HFB200604. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Enables drug discovery through single cell tech and AI analytics

Antibody for potential oncology treatment in clinical trials

Antibody targeting inflammatory and immunology diseases

People of HiFiBiO
Headcount 50-200
Employee Profiles 15
Board Members and Advisors 12
Employee Profiles
People
Yun-Yueh Lu
Senior Director, Discovery Biology & In Vivo Pharmacology
People
Liang Schweizer
Founder, Chairperson & CEO
People
Jinping Gan
VP, Global Head of Research
People
Steven Chen
General Counsel

Unlock access to complete

Board Members and Advisors
people
Leslie Kean
Scientific Advisor
people
Michael Croft
Scientific Advisor
people
Sebastian Amigorena
Scientific Advisor
people
Aurélien Marabelle
Scientific Advisor

Unlock access to complete

Funding Insights of HiFiBiO

HiFiBiO has successfully raised a total of $179.5M across 3 strategic funding rounds. The most recent funding activity was a Series D round of $75 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Series D — $75.0M
  • First Round

    (16 May 2018)

  • Investors Count 20
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2021 Amount Series D - HiFiBiO Valuation Mirae Asset Financial Services
Aug, 2019 Amount Series C - HiFiBiO Valuation IDG Capital
May, 2018 Amount Series B - HiFiBiO Valuation Sequoia Capital China , LYFE Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in HiFiBiO

HiFiBiO has secured backing from 20 investors, including venture fund and institutional investors. Prominent investors backing the company include Kite Pharma, Legend Holdings and Mirae Asset Financial Services. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Sequoia Capital is engaged in venture capital investments.
Founded Year Domain Location
-
Founded Year Domain Location
Tech & Offline focused early & growth stage VC firm investing in China
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by HiFiBiO

HiFiBiO has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include H-Immune. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Developing MAb immunotherapies to treat cancer
2016
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - HiFiBiO

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Hifibio Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of HiFiBiO

HiFiBiO operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Metabolon, Avidity Biosciences, Sutro Biopharma and Maze Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of pharmaceuticals and vaccines for various therapeutic areas
domain founded_year HQ Location
Solutions for biomarker discovery and diagnostic testing are provided.
domain founded_year HQ Location
Antibody-siRNA complexes are developed for cancer treatment.
domain founded_year HQ Location
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
domain founded_year HQ Location
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
domain founded_year HQ Location
Yeast cells are genetically engineered to produce medicinal products.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about HiFiBiO

When was HiFiBiO founded?

HiFiBiO was founded in 2013 and raised its 1st funding round 5 years after it was founded.

Where is HiFiBiO located?

HiFiBiO is headquartered in Paris, France.

Who is the current CEO of HiFiBiO?

Liang Schweizer is the current CEO of HiFiBiO. They have also founded this company.

Is HiFiBiO a funded company?

HiFiBiO is a funded company, having raised a total of $179.5M across 3 funding rounds to date. The company's 1st funding round was a Series B of $37.5M, raised on May 16, 2018.

What does HiFiBiO do?

HiFiBiO was established in 2013 in Paris, France, within the biotechnology sector. A platform is provided for antibody-based drug discovery, where entire B cell populations are screened through high-throughput, single-cell, functional methods. Next-generation sequencing and rapid DNA synthesis are integrated to target rare antibodies. Operations emphasize efficient identification and development of therapeutic candidates for pharmaceutical applications.

Who are the top competitors of HiFiBiO?

HiFiBiO's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.

What products or services does HiFiBiO offer?

HiFiBiO offers DIS® Platform, EMUNKITUG, and HFB200604.

How many acquisitions has HiFiBiO made?

HiFiBiO has made 1 acquisition, including H-Immune.

Who are HiFiBiO's investors?

HiFiBiO has 20 investors. Key investors include Kite Pharma, Legend Holdings, Mirae Asset Financial Services, Sequoia Capital, and Sherpa Healthcare Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available